WO2003037296A3 - Methods and dosage forms for improving the bioavailability of therapeutic agents - Google Patents

Methods and dosage forms for improving the bioavailability of therapeutic agents Download PDF

Info

Publication number
WO2003037296A3
WO2003037296A3 PCT/EP2002/012062 EP0212062W WO03037296A3 WO 2003037296 A3 WO2003037296 A3 WO 2003037296A3 EP 0212062 W EP0212062 W EP 0212062W WO 03037296 A3 WO03037296 A3 WO 03037296A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
therapeutic agent
release
dosage forms
bioavailability
Prior art date
Application number
PCT/EP2002/012062
Other languages
French (fr)
Other versions
WO2003037296A2 (en
Inventor
Laure Patricia Ouadji Njiki
Original Assignee
Aventis Pharma Gmbh
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Labopharm Inc filed Critical Aventis Pharma Gmbh
Priority to CA002466032A priority Critical patent/CA2466032A1/en
Priority to AU2002351798A priority patent/AU2002351798A1/en
Priority to EP02787522A priority patent/EP1439820A2/en
Priority to JP2003539640A priority patent/JP2005509643A/en
Priority to MXPA04004035A priority patent/MXPA04004035A/en
Publication of WO2003037296A2 publication Critical patent/WO2003037296A2/en
Publication of WO2003037296A3 publication Critical patent/WO2003037296A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention provides controlled release dosage forms for oral administration. The dosage form comprises a therapeutic agent that is metabolized in the upper GI tract in combination with a controlled-release agent so as to be hydrodynamically balanced so that, in contact with gastric fluid, the dosage form has a bulk density less than one g/ml and therefore is buoyant in the gastric fluid. Such dosage form is retained in the stomach during the tinme when substantially all of the medicaments are released therefroom. Additionally, such dosage form will release the medicament over an extended period of time so that delivery of the therapeutic agent to the small intestine will occur steadily rather than immediately. Such steady release over time of the therapeutic agent at the metabolisation and absorption site will prevent enyzme saturation and thereby exhibit greater bioavailability of the therapeutic agent.
PCT/EP2002/012062 2001-10-29 2002-10-29 Methods and dosage forms for improving the bioavailability of therapeutic agents WO2003037296A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002466032A CA2466032A1 (en) 2001-10-29 2002-10-29 Methods and dosage forms for improving the bioavailability of therapeutic agents
AU2002351798A AU2002351798A1 (en) 2001-10-29 2002-10-29 Methods and dosage forms for improving the bioavailability of therapeutic agents
EP02787522A EP1439820A2 (en) 2001-10-29 2002-10-29 Methods and dosage forms for improving the bioavailability of therapeutic agents
JP2003539640A JP2005509643A (en) 2001-10-29 2002-10-29 Methods and dosage forms for improving the bioavailability of therapeutic agents
MXPA04004035A MXPA04004035A (en) 2001-10-29 2002-10-29 Methods and dosage forms for improving the bioavailability of therapeutic agents.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01125761 2001-10-29
EP01125761.5 2001-10-29

Publications (2)

Publication Number Publication Date
WO2003037296A2 WO2003037296A2 (en) 2003-05-08
WO2003037296A3 true WO2003037296A3 (en) 2003-12-24

Family

ID=8179102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/012062 WO2003037296A2 (en) 2001-10-29 2002-10-29 Methods and dosage forms for improving the bioavailability of therapeutic agents

Country Status (6)

Country Link
EP (1) EP1439820A2 (en)
JP (1) JP2005509643A (en)
AU (1) AU2002351798A1 (en)
CA (1) CA2466032A1 (en)
MX (1) MXPA04004035A (en)
WO (1) WO2003037296A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962019B2 (en) 2005-09-09 2015-02-24 Angelini Pharma, Inc. Sustained drug release composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
JP5355002B2 (en) * 2008-09-10 2013-11-27 オリンパスメディカルシステムズ株式会社 Floating amount acceptance / rejection determination system, floating amount acceptance / rejection determination display system, floating amount acceptance / rejection determination method, and floating amount acceptance / rejection determination display method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055107A1 (en) * 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO2000015198A1 (en) * 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
WO2001010405A1 (en) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
WO2001058424A1 (en) * 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055107A1 (en) * 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO2000015198A1 (en) * 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
WO2001010405A1 (en) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
WO2001058424A1 (en) * 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUR AO AND ZHANG JS: "Captopril floating and/or bioadhesive tablets: design and release kinetics", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 26, no. 9, September 2000 (2000-09-01), ISSN: 0363-9045, pages 965 - 969, XP008002146 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962019B2 (en) 2005-09-09 2015-02-24 Angelini Pharma, Inc. Sustained drug release composition

Also Published As

Publication number Publication date
CA2466032A1 (en) 2003-05-08
AU2002351798A1 (en) 2003-05-12
EP1439820A2 (en) 2004-07-28
WO2003037296A2 (en) 2003-05-08
JP2005509643A (en) 2005-04-14
MXPA04004035A (en) 2004-10-29

Similar Documents

Publication Publication Date Title
WO2001056544A3 (en) Shell-and-core dosage form approaching zero-order drug release
EP1879566B1 (en) Compositions and methods for inhibiting gastric acid secretion
ES2006649A6 (en) Composition for the oral administration of pharmaceuticals
WO2005065654A3 (en) Rosiglitazone formulations
JP2003520223A5 (en)
AP2002002410A0 (en) Hydrodynamically Balancing Oral Drug Delivery System
JP2006527195A (en) Composition comprising triptan and NSAID
HRP20120754T1 (en) Dosage form containing pantoprazole as active ingredient
EA200700158A1 (en) MEDICAL FORMS WITH A TABLET NUCLEUS, COVERED WITH THE ENTEROROLEUBLISHING SHELL
WO2007048223A3 (en) A gastric retention drug delivery system
JP2005510485A5 (en)
WO2004002445A3 (en) Novel floating dosage form
KR20030045035A (en) Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
CA2304948A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
MY151230A (en) Novel method
AU2009247712B2 (en) Compositions and methods for inhibiting gastric acid secretion
WO2003037296A3 (en) Methods and dosage forms for improving the bioavailability of therapeutic agents
JP2003504338A5 (en)
HUP0203148A2 (en) Orally distintegrating composition comprising mirtazapine
WO2006023295A3 (en) Pharmaceutical compositions comprising effervescent agents and fenofibrate
WO2002069968A8 (en) New use
JPH0747534B2 (en) Tablets
WO2003037301A3 (en) Oral dosage forms for improving the bioavailability of therapeutic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2466032

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004035

Country of ref document: MX

Ref document number: 2003539640

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002787522

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002787522

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002787522

Country of ref document: EP